ImmunityBio, Inc. (IBRX) is a San Diego-based commercial-stage immunotherapy company whose lead asset, ANKTIVA, activates natural killer and T cells through an IL-15 receptor agonist and is approved in the United States for BCG-unresponsive non-muscle invasive bladder cancer. On Tuesday morning, the shares traded at $6.23, up $0.25 or 4.18%, from the prior session's close of $5.98. The direction was unambiguously higher, though the rebound only partially offsets a steep November decline. No new press release was issued Tuesday; the immediate reason cited by markets was a set of incremental clinical details delivered by management at London investor conferences on Monday, combined with a mechanically oversold set-up after six consecutive down sessions.
Speaking at the Jefferies and UBS healthcare conferences in London, Chief Executive Richard Adcock disclosed that the randomized, 370-patient QUILT-2.005 trial in BCG-naïve non-muscle invasive bladder cancer met its primary endpoint with a p-value of 0.01 — a statistical detail the company had not previously quantified when it announced the endpoint hit on November 9. He also said the company intends to submit its supplemental Biologics License Application to the FDA before the close of 2026, describing the document as in its final sections.
That matters because a BCG-naïve label would move ANKTIVA earlier in the treatment pathway, materially widening the eligible population beyond the BCG-unresponsive setting that currently drives revenue. Management also flagged that full response rates will be presented at a medical congress rather than in a press release, and referenced a nine-patient legacy study in which six evaluable patients remained in complete response roughly nine and a half years later with their bladders intact.
The disclosure itself is incremental rather than transformative, and the market needed a session to absorb it: the stock actually slipped 0.66% on Monday to $5.98 even as the comments circulated. Tuesday's bid looks like a delayed repricing of the filing timeline rather than a reaction to fresh news.
Context matters as much as the headline. IBRX fell in six consecutive sessions between November 9 and November 16, losing roughly 34% over the past month and sitting near $6 after peaking above $12.43 earlier in the year. The November 9 third-quarter report showed net product revenue of $48.7 million, up 53% year over year but down from $51.2 million in the second quarter and short of consensus near $59.2 million, with a GAAP net loss of $184.6 million. That combination drove a 17.7% single-day drop on more than 27 million shares.
With the stock stretched well below its 20-day, 50-day and 200-day moving averages and momentum readings near oversold territory, a counter-trend rally required little additional fuel. Short interest of roughly 126 million shares, equal to about 10.8 days of average trading volume, adds a reflexive element to any bounce.
The advance was not part of a broad industry move; no comparable sector or macro catalyst was identified for the session, which points to company-specific positioning. Turnover in the opening stretch was brisk but broadly consistent with the stock's normal pace of roughly 12.7 million shares a day, so the tape does not suggest institutional accumulation on a large scale. Technically, the shares remain in a downtrend: resistance sits near the $7.90–$8.60 band formed by the 20-day and 50-day averages, while the $5.75–$5.80 area marked last week's low is the nearest support reference. The beta above 2 underscores how quickly sentiment can reverse in either direction.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price reaction. This event lands at 23 out of 100.
The verified news was moderate at best: a sharper statistical detail and a restated filing timeline for a trial whose success was already public, with response rates still withheld. The price response was unremarkable by the stock's own standards — the 4.18% gain was only about 1.1 times its typical daily move of roughly 3.85%, and swings of that magnitude or larger occurred in 24 of the last 69 sessions. Weak news plus an ordinary move produces a low score.
The central event is the supplemental BLA submission for the BCG-naïve indication, expected before the end of 2026, followed by FDA review timelines that will govern any label expansion. Investors also await the full QUILT-2.005 response rates at a medical meeting, the first real test of how much benefit ANKTIVA adds over BCG alone. Commercially, attention will focus on whether the broader October label drives sequential revenue growth into 2027, after a September quarter that showed deceleration. All four covering analysts rate the shares a buy, though estimates still imply a per-share loss this year. The principal risks are unchanged: $334.3 million of cash against roughly $75 million of quarterly operating burn, going-concern language in the latest quarterly report, dilution from at-the-market sales, and the possibility of a regulatory delay. Fourth-quarter results are expected in late February 2027.
Tickeron's Trending AI Robots page is a curated view of automated trading strategies that are performing best under present market conditions. Rather than listing every model, it surfaces only the strongest performers from a library of hundreds of AI bots covering thousands of tickers. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured set rotates as volatility and leadership change. For readers tracking high-beta names like this one, it is a practical starting point for comparing systematic approaches side by side.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 33 cases where IBRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 84 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for IBRX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.586). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of cancer treatment products
Industry Biotechnology